Alector Inc

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alector Inc reports robust earnings, advances Alzheimer's therapy development

Alector Inc's Q2 2023 earnings call highlighted strong financial performance, progress in late-stage clinical programs, and a focus on immuno-neurology research.
The company faces challenges in trial management and disease progression variability but benefits from a solid cash position and collaboration revenue.
Opportunities lie in upcoming milestones, conference participation, and the potential of AL002 therapy, positioning Alector for continued growth and innovation.

Alector Inc reports strong Q4 performance and advances in neurodegenerative treatments

Alector Inc's Q4 performance reflects significant achievements in late-stage programs, strong financial standing, and positive patient engagement, underlining progress in neurodegenerative disease treatment.
The company's strengths in immuno-neurology, blood-brain barrier technology, and strategic partnerships position them well for addressing Alzheimer's disease and exploring accelerated approval pathways.
Challenges in trial design, biomarker assessment, and resource allocation require careful navigation, while opportunities in therapeutic delivery enhancement and disease progression slowing offer avenues for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alector Looks Like A Buy After Huge Selloff

SOUTH SAN FRANCISCO, Calif., Aug.  04, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET.

Alector to Present at the BTIG Virtual Biotechnology Conference 2020

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.

Why Alector  Is Tumbling 28.7% Today

SOUTH SAN FRANCISCO, Calif., July  28, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced preliminary data from its Phase 1b and open-label Phase 2 studies of AL001, for the treatment of people with frontotemporal dementia with a progranulin gene (GRN) mutation (FTD-GRN). AL001 is the company’s wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain. The data were presented today at the virtual 2020 Alzheimer’s Association International Conference (AAIC) by Robert Paul, M.D., Ph.D., chief medical officer of Alector.

Alector Announces Promising Preliminary Data from AL001 Phase 1b and Phase 2 Open-Label Long-Term Dosing Study of People with Frontotemporal Dementia

SOUTH SAN FRANCISCO, Calif., July  24, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced dosing of the first patient in its pivotal Phase 3 clinical trial, named INFRONT-3, evaluating AL001 in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN). AL001 is the company’s wholly owned, investigational human monoclonal antibody designed to modulate progranulin, a key regulator of immune activity in the brain. 

Alector Doses First Patient in Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 in Patients with Frontotemporal Dementia

SOUTH SAN FRANCISCO, Calif., July  21, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia at the upcoming 2020 Alzheimer’s Association International Conference being held virtually, July 27-31, 2020.

Alector to Present Data from the AL001 Phase 2 Open-Label Study in Frontotemporal Dementia at the 2020 Alzheimer’s Association International Conference

SOUTH SAN FRANCISCO, Calif., May  13, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical- stage biotechnology company pioneering immuno-neurology, today announced business highlights and financial results for the first quarter ended March 31, 2020.

Alector Reports 2020 First Quarter Financial Results and Business Highlights

Is  (ALEC) Outperforming Other Medical Stocks This Year?

Is Alector (ALEC) Outperforming Other Medical Stocks This Year?

SOUTH SAN FRANCISCO, Calif., March  25, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that harness the innate immune system, and Innovent Biologics, a leading Chinese biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, jointly announced today the execution of a regional licensing agreement to develop and commercialize AL008 for oncology indications in China.

Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China

Alector (ALEC) delivered earnings and revenue surprises of -2.27% and -37.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q4 Loss, Misses Revenue Estimates

SOUTH SAN FRANCISCO, Calif., March  23, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) today announced the addition of Paula Hammond, Ph.D., to the Company’s Board of Directors. Dr. Hammond is the David H. Koch Chair Professor of Engineering and Department Head, Chemical Engineering at the Massachusetts Institute of Technology (MIT), a member of MIT’s Koch Institute for Integrative Cancer Research and a founding member of the MIT Institute for Soldier Nanotechnology.

Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors

Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alector (ALEC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alector (ALEC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Alector (ALEC) a New Buy Stock

Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?

Alector (ALEC) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Why Alector (ALEC) Could Be Positioned for a Surge

SOUTH SAN FRANCISCO, Calif., Feb.  05, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AL101 for the treatment of patients with progranulin gene mutations causative of frontotemporal dementia (FTD-GRN). AL101, the company’s second product candidate designed to restore progranulin levels in the brain, is currently being evaluated in a Phase 1 trial in healthy volunteers.

Alector Announces FDA Fast Track Designation Granted to AL101 for the Treatment of Patients with Frontotemporal Dementia

-     Total gross proceeds from the offering to Alector are approximately $240 million -     Total gross proceeds from the offering to Alector are approximately $240 million

Alector Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million Total gross proceeds from the offering to Alector, including from the sale of the additional shares, are expected to be approximately $240 million

Alector Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering

Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million Public Offering of 8,350,000 Shares of Common Stock for Gross Proceeds of Approximately $208 Million

Alector Announces Upsizing and Pricing of Public Offering

Alector: A Promising Neuro-Immunology Pick For 2020

SOUTH SAN FRANCISCO, Calif., Jan.  06, 2020  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December 2019, it initiated dosing in healthy volunteers in its Phase 1 study of AL101, an investigational product candidate designed to increase progranulin levels. The Phase 1 study is designed to assess the safety and tolerability of AL101 in healthy volunteers, as well as the pharmacokinetics (PK), pharmacodynamics (PD) and bioavailability of intravenously and subcutaneously administered doses of AL101.

Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases

SOUTH SAN FRANCISCO, Calif., Dec.  20, 2019  (GLOBE NEWSWIRE) -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 23, 2019.

Alector Added to the NASDAQ Biotechnology Index

Amgen

Fulcrum Therapeutics Inc

Ultragenyx Pharmaceutical

Schnitzer Steel Industries Inc

SAGE Therapeutics

Sarepta Therapeutics

Vertex Pharmaceuticals

Biotech investing is risk-fraught, but for investors who make the right bets, the returns can be staggering.

8 Biotech Stocks Morgan Stanley Recommends For 2020

During its R&D day, company announced that Drs. Scheller and Südhof will support its mission to pioneer the discovery and development of transformative immune therapies for neurodegeneration During its R&D day, company announced that Drs. Scheller and Südhof will support its mission to pioneer the discovery and development of transformative immune therapies for neurodegeneration

Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr.

SOUTH SAN FRANCISCO, Calif., Dec.  11, 2019  (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as the company’s president and chief operating officer. In this new role, Dr. Suliman will oversee Alector’s day-to-day operations, including preclinical development, program management, and strategic and administrative functions. Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.

News for Alector Inc Stock (ALEC)